Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors
Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors
复制标题
DOI：
10.21873/anticanres.13935
复制
发表时间：
2020-01-01
影响因子：
2
通讯作者：
Buechler, Christa
中科院分区：
文献类型：
--
作者：
Feder, Susanne;Kandulski, Arne;Buechler, Christa
背景/目的：脂联素可以预防代谢疾病和癌症。因此，结直肠癌（CRC）患者血清脂联素降低。肝保护因子在肝细胞癌（HCC）中明显增加。结直肠癌转移到肝脏是常见的，本研究的目的是评估血清脂联素是否能区分原发性和继发性肝癌。材料与方法：采用ELISA法检测36例结直肠癌肝转移患者、32例HCC患者和49例无癌患者血清脂联素水平。结果：肿瘤患者血清脂联素水平高于非肿瘤患者。脂联素与肝癌TNM分期及血清肿瘤标志物水平无关。此外，肝脏炎症和肝纤维化与血清脂联素水平无关。代谢性疾病与低脂联素和更高的癌症风险有关。在HCC中，而在结直肠癌血清中，高血压和高尿酸血症患者的脂联素升高。在这个队列中，脂联素与趋化素正相关，趋化素是一种被认为有助于代谢紊乱的脂肪因子。结论：血清脂联素不能区分原发性和继发性肝脏肿瘤。
Background/Aim: Adiponectin protects from metabolic disease and cancer. Accordingly, serum adiponectin was reduced in patients with colorectal cancer (CRC). This hepatoprotective factor was definitely increased in hepatocellular carcinoma (HCC). CRC metastases to the liver are common and the aim of the present study was to evaluate whether serum adiponectin discriminates primary from secondary liver cancers. Materials and Methods: Adiponectin was measured by ELISA in the serum of 36 patients with colorectal liver metastases, 32 patients with HCC and 49 patients without cancer. Results: Serum adiponectin levels were higher in cancer than non-tumor patients. Adiponectin was not related to TNM stage in HCC nor to the levels of serum tumor markers. Moreover, hepatic inflammation and liver fibrosis were not correlated with serum adiponectin levels. Metabolic diseases are associated with low adiponectin and a higher risk of cancer. In HCC, but not in CRC serum, adiponectin was increased in patients with hypertension and hyperuricemia. In this cohort, adiponectin positively correlated with chemerin, an adipokine supposed to contribute to metabolic disturbances. Conclusion: Serum adiponectin cannot discriminate primary from secondary liver tumors.